NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC raised its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 19.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 354,975 shares of the company’s stock after acquiring an additional 57,806 shares during the period. ArrowMark Colorado Holdings LLC owned 0.39% of NewAmsterdam Pharma worth $5,893,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in NAMS. Banque Cantonale Vaudoise acquired a new stake in shares of NewAmsterdam Pharma in the second quarter valued at approximately $38,000. Bellevue Group AG purchased a new position in NewAmsterdam Pharma during the 3rd quarter worth $128,000. Rosalind Advisors Inc. acquired a new position in NewAmsterdam Pharma in the second quarter valued at $194,000. Wolverine Asset Management LLC raised its holdings in shares of NewAmsterdam Pharma by 117.7% in the second quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock valued at $298,000 after buying an additional 8,394 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in shares of NewAmsterdam Pharma by 49.1% during the second quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after buying an additional 8,087 shares during the period. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Price Performance

NAMS opened at $19.64 on Tuesday. NewAmsterdam Pharma has a 12 month low of $8.90 and a 12 month high of $26.35. The business has a 50 day simple moving average of $19.55 and a 200-day simple moving average of $18.57.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Piper Sandler reissued an “overweight” rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, November 21st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $33.80.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 45,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $25.08, for a total value of $834,486.84. Following the completion of the transaction, the insider now directly owns 11,778,760 shares of the company’s stock, valued at $295,411,300.80. The trade was a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 86,803 shares of company stock valued at $1,755,307. 19.50% of the stock is owned by company insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.